Medpace Q2 2026 Earnings Preview
Seeking Alpha ·
Medpace ( MEDP ) is scheduled to announce Q2 earnings results on Wednesday, July 22nd, after market close. The consensus EPS estimate is $4.00, and the consensus revenue estimate is $688.81M (+14.2% Y/Y). Over the last 1 year, MEDP has beaten EPS
AI 시장 분석
As Medpace is scheduled to release its Q2 2026 earnings after the market close on July 22, the market consensus stands at an EPS of $4.00 and revenue of $688.81 million, expected to grow 14.2% year-over-year. Over the past year, MEDP has consistently reported strong earnings, maintaining high trust. Investors should closely monitor the sustainability of Contract Research Organization (CRO) demand and changes in guidance during this earnings release.
상승 영향
- Biotechnology — Expected revenue of $688.81 million represents a 14.2% year-over-year growth, indicating active R&D investment across the pharmaceutical and biotechnology sectors.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 61% · Bearish (Short) 39%
465 participants
Related News
- AAR expects Q1 FY2027 sales growth of 21% to 23% excluding legacy commercial programs, while targeting margin expansion
- Steel Dynamics targets exiting 2026 at at least 90% aluminum capacity while reaffirming $650M-$700M through-cycle EBITDA
- Jamie Dimon's Latest Warning Sends Shockwaves Through Wall Street. History Is Very Clear About What Happens Next.
- Is This the Most Undervalued Sector ETF on the Market?
- Oklo, X-Energy to join Trump administration effort to speed nuclear reactors for AI - Bloomberg
- Why Tutor Perini Stock Trounced the Market on Tuesday
